MS4A1 and neutropenia: In another case series and systematic review focusing on neutropenia complicating anti-CD20 treatment, the average onset of neutropenia was observed after two treatment cycles, with delayed neutropenia occurring approximately 90 days after a treatment (Rossi et al., 2022).